Vision
Every lung disease patient diagnosed & treated at the earliest possible stage with the best treatment
It’s about finding the patients, many of whom are asymptomatic, and accelerating their time to diagnosis, care and ultimately cure.
Mission
Our lung AI precision-care platform powering earlier diagnosis, better treatment decisions & life-saving procedures in every hospital.
As with just about any health problem, knowing earlier gives you and your healthcare provider the opportunity to intervene... [before] treatment options are limited
Dr. MeiLan Han, Professor of Medicine and pulmonologist at University of Michigan
Hear from one of our founders
I lead the Clinical Evidence team at Optellum. We handle two big areas within the business. First, we work on publishing evidence demonstrating the value of Optellum's innovations. These studies play a crucial role in gaining the trust of clinicians, academic and industry partners, and ultimately of patients and their families. Secondly, we handle the bespoke curation and detailed understanding of the huge medical imaging datasets driving our technical innovation, because even the best AI model out there needs quality data to learn from. In a world full of bias, that's a really pertinent problem to work on for the good of everyone equitably.
I co-founded Optellum because I could see how much benefit machine learning technology could bring to understanding lung data, and growing Optellum is the best way to put these cutting-edge innovations where they can really benefit patients.
Dr Lyndsey Pickup
Head of Clinical Evidence & co-founder
Our history
-
arrow_cool_down
2016
Optellum founded by former Oxford University Computer Vision lab scientists -
arrow_cool_down
2018
Optellum Virtual Nodule Clinic® & LCP AI ready.
Pre-market feedback obtained -
arrow_cool_down
2019
VC-led seed round.
$4 million for further clinical evidence & regulatory clearance -
arrow_cool_down
2020
Publications with top KOLs.
First external validation studies published -
arrow_cool_down
2021
Regulatory clearance in UK & US for VNC.
510(k) clearance with FDA and CE / UKCA marking.
Large-cap MedTech partnership deal.
Fuel development of pulmonology indications-for-use expansion -
arrow_cool_down
2022
VC-led series A funding.
$14 million to expand team and commercialize
CPT codes & CMS payment classification.
Medicare reimbursement generating more ROI for hospitals.
Large-cap MedTech distribution deal.
Strategic partnership for worldwide distribution -
arrow_cool_down
2023
Large-cap Pharma partnership deal.
Development of novel AI-enabled therapy guidance.
Strategic MedTech pilot project start.
Multi-site deployment & post-market evidence generation.
Zero-click LCP AI ready for clearance.
Automated nodule detector helping expand suite of offerings -
arrow_cool_down
2024
World's largest chest CT dataset.
Key milestones reached in NHS-led DART study.
AI therapy guidance platform launch.
LCP-ROR (risk of recurrence) outperforms standard staging.
Guideline-relevant evidence publication.
LCP AI outperforms standard-of-care clinical risk models.
Real-world impact results.
Real-world customer results show transformative patient benefit
Careers at Optellum
We’re building an exceptional team to shape the future of early intervention in lung cancer and lung disease
Optellum is trusted by industry & academic leaders